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The environmental factors that contribute to the hom-
ing of T cells in skin disease is unknown. The skin
lesions of atopic dermatitis (AD) are frequently colon-
ized with superantigen (SAg), producing strains of
Staphylococcus aureus. In vitro, these superantigens have
the capacity to activate and expand T cells expressing
specific T cell receptor BV gene segments, and also to
increase their skin homing capacity via upregulation
of the skin homing receptor, cutaneous lymphocyte-
associated antigen (CLA). These activities have been
proposed to enhance the chronic cutaneous inflamma-
tion of AD, but an in vivo role for SAg has not been
conclusively demonstrated. In this study, we sought
direct evidence for in vivo SAg activity by comparing
the SAg profiles of S. aureus cultured from the skin of
AD subjects to the T cell receptor Vb repertoire of
their skin homing (CLAF) T cells in peripheral blood.
SAg secreting S. aureus strains were identified in six of
Atopic dermatitis (AD) is a complex chronic inflam-matory skin disorder affecting 10%–15% of childrenand is a major cause of occupation-related disabilitycaused by skin disease (Schultz-Larsen et al, 1986). Itis associated with cutaneous erythema, induration,
severe pruritus, elevated serum IgE, eosinophilia, and a disposition
towards extracutaneous atopic manifestations such as allergic rhinitis
and/or asthma (Hanifin and Rajka, 1980). AD lesions are character-
ized by cellular infiltrates comprised of memory T cells expressing
the skin homing receptor cutaneous lymphocyte-associated antigen
(CLA), and monocyte/macrophages (Leung, 1995). Recent studies
indicate that the T cell activation in AD is biphasic with activation
of the Th 2-like cytokines, IL-4, IL-5, and IL-13, during the acute
phase of the eruption (Van der Heijden et al, 1991; Hamid et al,
1994). The chronic inflammatory AD skin lesion, however, is
associated with increased expression of the Th 1 cytokines, inter-
feron-gamma and IL-12 (Grewe et al, 1994; Hamid et al, 1996).
Allergens are thought to play a role in the initiation of the skin
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12 AD patients, and all of these subjects manifested
significant SAg-appropriate Vb skewing within the
CLAF subsets of both their CD4F and their CD8F
T cells. T cell receptor Vb skewing was not detectable
among the overall CD4F or CD8F T cell subsets of
these subjects, and was not present within the CLAF
T cell subsets of five patients with plaque psoriasis and
10 normal controls. T cell receptor BV genes from
the presumptively SAg-expanded populations of skin
homing T cells were cloned and sequenced from three
subjects and, consistent with a SAg-driven effect, were
found to be polyclonal. We conclude that SAg can
contribute to AD pathogenesis by increasing the fre-
quency of memory T cells able to migrate to and
be activated within AD lesions. Key words: CLA/
inflammation/SEB/TSST-1. J Invest Dermatol 112:249–
253, 1999
lesion by promoting Th2-like cytokine gene expression via the
activation of T cells and mast cell degranulation (Leung, 1995);
however, the mechanisms that contribute to the chronic phase of
the skin lesion are unknown.
AD is often associated with skin colonization by Staphylococcus
aureus (Leyden et al, 1974). In many cases these bacteria are known
to produce superantigens (SAg) (Leung et al, 1993a; McFadden
et al, 1993), which have the capacity to directly activate T cells
bearing appropriate T cell receptor (TCR) Vβ domains (Marrack
and Kappler, 1990). SAg can also induce T cell expression of CLA
via an IL-12 dependent mechanism (Leung et al, 1995). Thus, SAg
may contribute to the pathogenesis of AD by activating large
cohorts of T cells within lesions (far more than conventional
antigens) and by increasing the population of memory T cells
capable of efficient extravasation to skin. Such mechanisms may
act to maintain T cell activation in skin and thus perpetuate AD
lesions even when the initiating allergen may be absent.
A role for SAg in AD pathogenesis is supported by observations
showing antibiotics to be an effective treatment of AD (Lever et al,
1988) and that SAg can induce eczematoid skin reactions in patch
test models (Strange et al, 1996); however, because only about 50%
of S. aureus are SAg producing, the pathogenic role of SAg in this
disease remains a source of controversy. In this study, we sought
direct evidence for SAg involvement in AD by determining
whether the presence of a particular SAg in skin lesions of AD
subjects would predict an expansion of appropriate (SAg-associated)
TCR-Vβ bearing T cells in peripheral blood, especially in the
CLA1 skin-homing memory T cell subset.
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MATERIALS AND METHODS
Patients Twelve AD patients were recruited for study (mean age 5 36),
all of whom fulfilled the criteria of Hanifin and Rajka (1980). Four of the
AD patients had S. aureus cultures positive for Staphylococcal enterotoxin
B (SEB), two had S. aureus cultures positive for toxic shock syndrome
toxin-1 (TSST-1), and the remaining six patients were positive for
S. aureus, but negative for any known SAg (analyzed by enzyme-linked
immunosorbent assay of staphylococcal skin culture supernatants, Toxin
Technologies, Sarasota, FL). Normal healthy volunteers (n 5 10, mean
age 5 32) and plaque psoriasis patients (n 5 5, mean age 5 35) with no
history of atopy were used as control groups. All patients had greater than
20% skin involvement and were not receiving prednisone at the time
of study.
Preparation of peripheral blood mononuclear cells (PBMC)
Heparinized venous blood was layered on a Ficoll-Paque density gradient
(Pharmacia, Piscataway, NJ) and centrifuged for 25 min at 400 3 g at
room temperature. The PBMC layer was aspirated and washed in Hanks
balanced salt solution (Gibco-BRL, Grand Island, NY). Cells were re-
suspended in Hanks balanced salt solution and counted. PBMC were
always .95% viable, as determined by a trypan blue (Sigma, St. Louis,
MO) exclusion assay.
Immunofluorescense staining for Vb-fluorescence-activated cell
sorter (FACS) analysis Staining for TCR Vβ expression and analyses
was carried out as we previously described (Abe et al, 1993). Briefly,
PBMC were washed in phosphate-buffered saline (PBS) and resuspended
at 10 3 106 cells per ml in a staining solution [PBS with 5% fetal calf
serum (Gibco), 1% immunoglobulin (Alpha Therapeutic, Los Angeles,
CA), 0.02% sodium azide (Sigma)]. Cells were stained in 96 well, round
bottomed plates with a panel of biotinylated monoclonal antibodies against
human Vβ2, 3, 5.1, 8, 12, 13.1, 13.2, and 17, then incubated for 30 min
at 37°C in the dark as previously described (Abe et al, 1993). After the
incubation period, cells were washed twice with washing buffer [PBS, 5%
fetal calf serum (Gibco), 0.02% sodium azide (Sigma)] by centrifugation at
300 3 g for 5 min at 4°C. Cell pellets were resuspended in staining
solution and incubated with anti-CD3 allophycocyanin, anti-CD4 peridinin
chlorophyll protein (Becton Dickinson, San Jose, CA), CLA-fluorescein
isothiocyanate (Immunotech, Maine, FL) and a streptavidin phycoerythrin
conjugate (Immunotech) for 30 min at 4°C. Stained cells were again
washed twice in washing buffer and once in 1 3 PBS by centrifugation at
300 3 g for 5 min at 4°C. Finally, the cells were fixed in 300 µl of
1% (vol/vol) formaldehyde (Polysciences, Warrington, PA) in 1 3 PBS.
Analysis was performed using four color flow cytometry (FACSCalibur,
Becton Dickinson).
Separation of CLAF and CLA– PBMC populations by
FACS Freshly isolated PBMC (100 3 106) were incubated with 1 ml
of a 20% dilution of fluorescein isothiocyanate conjugated rat anti-human
CLA monoclonal antibody in 500 µl of staining solution, for 30 min at
4°C as previously described (Abernathy-Carver et al, 1995). Cells were
resuspended and washed twice in 5 ml of PBS by centrifugation at 300 3 g
for 10 min at 4°C. Cells were resuspended in PBS and sorted into CLA1
and CLA– populations by FACS (Coulter Epics). CLA1 T cells were
always greater than 98% pure.
Preparation of RNA and reverse transcriptase-polymerase chain
reaction (PCR) Total RNA was prepared from CLA1 and CLA–
PBMC using a commercially available kit according to the manufacturer’s
instructions (RNAid Plus, Bio 101, La Jolla, CA). First strand cDNA was
synthesized at 37°C for 1 h in a 20 µl reaction mixture containing 1 µl of
50 ng per µl random hexamers (Gibco-BRL), 4 µg RNA, 10 U RNAse
inhibitor (Promega, Madison, WI), 1 µl 10 mM dNTP (Gibco-BRL), and
200 U Superscript reverse transcriptase (Gibco-BRL). After the synthesis
period, the reverse transcriptase was denatured for 10 min at 95°C. cDNA
was PCR amplified in a 50 µl reaction mixture containing 5 µl of
10 3 PCR buffer II (Perkin Elmer, Branchberg, NJ), 5 µl of 25 mM
MgCl2, 8 µl of 10 mM dNTP (Gibco-BRL), 1.5 U Taq-gold DNA
polymerase (Perkin Elmer), 4 µl cDNA, and 2.5 µl of each primer (6 µM).
The primer sequences were as follows:
TCRBV2, 59-TCA TCA ACC ATG CAA GCC TGA CCT-39
TCRBV17, 59-CAG ATA GTA AAT GAC TTT CAG-39
TCRBC, 59-TTC TGA TGG CTC AAA CAC-39
The reaction mixture was denatured for 1 min at 95°C, annealed for
1 min at 55°C, and extended for 1 min at 72°C, for 35 cycles on a DNA
thermal cycler (Perkin Elmer).
Sequencing of PCR products encoding TCRBV genes PCR prod-
ucts were visualized on a 2% agarose (Boehringer, Indianapolis, IL), 0.05%
ethidium bromide (Sigma), 1 3 tris borate electrophoresis buffer gel.
Products of the correct size were ligated overnight at 14°C in a 10 µl
reaction mixture containing 1 µl PCR product, 1 µl of 10 3 ligation
buffer (Invitrogen, Carlsbad, CA), 4 U T4 DNA ligase (Invitrogen),
0.05 µg pCR-II plasmid vector (Invitrogen), and 5 µl sterile water. The
supercompetent bacterial strain, Epicurean coli, XL-1 Blue (Stratagene, La
Jolla, CA) was transformed with the ligated plasmids. In brief, 40 µl aliquots
of bacteria were treated with 2 µl of 0.5 M β-mercaptoethanol (Invitrogen)
for 10 min at 4°C. Two microliters of individual ligation products were
added to separate bacterial suspensions for 30 min at 4°C. The bacteria
were heat shocked for 50 s at 42°C, and grown for 1 h at 37°C in SOC
medium (Invitrogen). Bacteria were plated on agar plates (1.5% agar, Difco,
Detroit, MI), 1% Bactopeptone (Difco), 1% yeast extract (Difco), 0.5%
sodium chloride (Sigma), 50 µg kanamycin (Solopak, Elk, IL) per ml,
20 µl of 0.2 M isopropylthiogalactoside (IPTG, Gibco-BRL), 40 µl of
10% 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal, Gibco-BRL),
and incubated overnight at 37°C. Positive colonies were incubated over-
night in 5 ml Luria-Bertani medium at 37°C, then the plasmids were
purified using a commercial purification system (Qiagen, Santa Clarita,
CA). Five microliters of each plasmid preparation was digested with 20 U
of EcoRI (Gibco-BRL) in 1 3 REact III buffer (Gibco-BRL) for 1 h at
37°C. Digests were then electrophoresed on a 2% agarose (Boehringer),
0.05% (vol/vol) ethidium bromide (Sigma), 1 3 tris borate electrophoresis
buffer gel. Products of the correct size were sequenced using an automated
sequencing system. In brief, a reaction mixture was composed of 1.6 µl of
a 6 µM sequencing primer (TCRBC, –59-CGA CCT CGG GTG GGA
ACA-39), 4 µl plasmid DNA, and 4 µl of dye terminator mix (Perkin
Elmer). The reaction mixture was denatured for 30 s at 95°C, annealed
for 15 s at 50°C, and extended for 4 min at 60°C, for 25 cycles on a DNA
thermal cycler (Perkin Elmer). Reaction products were electrophoresed on
a 4.5% (wt/vol) acrylamide (Biorad, Hercules, CA), 6 M urea (Sigma),
1 3 tris borate electrophoresis buffer gel, and analyzed using an automated
sequencing system (Applied Biosysytems/Perkin Elmer).
Statistical analysis Vβ FACS data were log-transformed prior to analysis
in order to produce more normally distributed residuals. The mean Vβ
expression between study groups was then compared using a one-way
ANOVA test. Association between specific Vβ skewing and the SAg being
produced was assessed using a standard χ2-test.
RESULTS
The TCR Vβ repertoire of PBMC from AD patients with SEB-
producing S. aureus (n 5 4), TSST-1-producing S. aureus (n 5 2),
or non-SAg-producing S. aureus (n 5 6) were analyzed by FACS.
Plaque psoriasis patients (n 5 5) and nonatopic healthy individuals
(n 5 10) served as controls. Within the CLA1, skin homing
population (Fig 1), an elevation of T cells bearing the SEB-
reactive TCR, Vβ17, was observed in patients with SEB-producing
S. aureus. In patients with TSST-1-producing S. aureus, there was
an elevation of Vβ21 T cells (Fig 1). This is a TCR known to be
stimulated by TSST-1. This elevation of Vβ21 and Vβ171 T cells
in AD patients with SAg-producing S. aureus was observed within
both the CD41 and the CD81 subpopulations (Fig 2a, b, respect-
ively), consistent with a SAg driven response. It is of note that a
single patient with SEB-producing S. aureus did show an elevation
in the Vβ2 CD41 T cell population (Fig 2a); however, this
elevation was not observed in the CD81 population, indicating
this was more likely to be an antigen-driven, rather than a
SAg-driven expansion. No statistical difference was found in the
percentage of CLA1 T cells between the three goups (AD with
SAg-producing S. aureus, mean 5 9.8% 6 2.3; AD with non-
SAg-producing S. aureus, mean 5 8.9% 6 1.5; psoriasis patients,
mean 5 11.3% 6 2.6). These data show that, within the CLA1
skin homing T cell population, there was an expansion of SAg
reactive T cells which was specific to the SAg being produced in
each patient. Moreover, this correlation was found to be statistically
significant (p , 0.0001).
CLA1 T cells from three AD patients were isolated by FACS
cell sorting and examined for TCR-Vβ chain junctional region
and NDβN region diversity. From a single patient with SEB-
producing S. aureus and Vβ171 T cells (Table I) increased to 2.9
times the median value for normals, 47 clones were sequenced. If
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Figure 1. AD patients with SAg-
producing S. aureus show an elevation
in SAg-reactive, CD31 skin homing
T cells. Immunophenotyping of the T cell
repertoire within the skin homing, CLA1/
CD31 T cell population was performed.
The hatched boxes represent the 2.5th to
97.5th percentile values for normal
individuals. Elevations in Vβ21 and Vβ171
T cells were observed in patients with
TSST-1- (n 5 2) and SEB- (n 5 4)
producing S. aureus, respectively.
Figure 2. Expansion of SAg-reactive T
cells in both CD4 and CD8
subpopulations. (a) AD patients with
SAg-producing S. aureus show an elevation
in SAg-reactive, CD41 skin homing
T cells. Immunophenotyping of the T cell
repertoire within the CLA1/CD41 T cell
population was performed. Elevations in
Vβ21 and Vβ171 T cells were observed in
patients with TSST-1- and SEB-producing
S. aureus, respectively. (b) AD patients with
SAg-producing S. aureus show an elevation
in SAg-reactive, CD81 skin homing
T cells. Immunophenotyping of the T cell
repertoire within the CLA1/CD81 T cell
population was performed. Elevations in
Vβ21 and Vβ171 T cells were observed in
patients with TSST-1 and SEB producing
S. aureus, respectively.
Table I. The expanded population of SAg-reactive, skin
homing T cells from AD patients with SAg-producing
S. aureus, comprise a polyclonal population
SAg BV elevation No. of clones No. of identical
Patient produced (fold increase) sequenced sequences
LM SEB BV17 (32.9) 47 2
RG TSST-1 BV2 (32.1) 33 0
KC TSST-1 BV2 (32.0) 21 0
this was an antigen-driven response one would predict that 67%
of the sequences obtained would be the same; however, of the
sequences obtained, only two of the 47 were found to be identical.
From the two patients with TSST-1-producing S. aureus and
elevated Vβ21 T cells (Table I), all sequences were different.
These data demonstrate that the increased expression of SAg
reactive T cells in the skin homing population was polyclonal,
again indicative of a SAg-driven response.
Some patients with non-SAg-producing S. aureus also showed
elevations in Vβ8, Vβ13.1, and Vβ13.2 T cells in the skin homing
population (Fig 1); however, these elevations occurred in either
the CD41 or the CD81 only, never in both CD41 and CD81 T
cell subsets. Within the total CD31 T cell population a significant
expansion of Vβ81 T cells was observed in the AD group with
non-SAg-producing S. aureus (Fig 3, p , 0.05) as compared with
the other study groups. This expansion was found to be solely
within the CD81 population and was statistically significant when
compared with the other study groups (Fig 4b, p , 0.05).
Moreover, sequence analysis of TCR-Vβ81 T cells from peripheral
blood T cells of patients with elevated Vβ8, demonstrated an
oligoclonal expansion (data not shown) indicative of an antigen-
driven process. Two individuals, in the non-SAg-producing AD
group, showed an elevation of TCR-Vβ81 T cells in the CD41
population (Fig 4a, closed triangles), but this was not observed in
their CD81 population (Fig 4b).
DISCUSSION
This study has demonstrated that subjects with AD and skin
colonization with SAg-producing S. aureus manifest expanded
populations of circulating skin homing (CLA1) memory T cells
that express TCR appropriate for the SAg being produced on their
skin surface. TSST-1-producing S. aureus correlated with expansions
of CLA1 T cells bearing the TSST-1-reactive TCR Vβ2, whereas
SEB-producing S. aureus correlated with expansions of CLA1
T cells bearing the SEB reactive TCR Vβ17. Interestingly, expanded
populations of Vβ3- and Vβ12-bearing CLA1 T cells were not
observed in subjects with SEB-producing S. aureus, despite the fact
that SEB also reacts with these TCR (Kotzin et al, 1993). This
observation may reflect our recent finding that Vβ17 is the most
reactive TCR for this SAg (DYM Leung, unpublished observation).
SAg stimulate both CD41 and CD81 T cell subsets. Consistent
with this property of SAg, elevated frequencies of SAg-reactive
T cells were found within both the CD41 and the CD81
populations. Further support for these TCR Vβ expansions being
SAg driven (as opposed to antigen driven) is provided by our TCR
gene sequencing data, which demonstrated that the expanded Vβ21
and Vβ171 skin homing T cells were polyclonal. Expansions of
SAg-reactive T cell populations could not be discerned among the
overall CD41 and CD81 T cell populations, indicating the SAg
effect is largely, if not completely, restricted to the CLA1 skin
homing subset. Taken together, these data strongly support the
hypothesis that S. aureus secretion of SAg in the lesional skin of
AD subjects has definite effects on the repertoire of the recirculating,
skin homing memory T cells.
The restriction of the expanded Vβ-restricted T cell populations
to the CLA1 memory T cell subset shown here, as well as the general
linkage between SAg pathophysiology and skin inflammation, is
likely related to the ability of SAg to upregulate CLA expression
on the T cells they activate (Leung et al, 1995). We have previously
shown that CLA upregulation is an indirect effect of SAg. In
addition to their T cell activating properties, SAg induce IL-12
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Figure 3. Vb81 T cells are expanded
within the total peripheral blood T cell
population. Immunophenotyping of the
CD31, T cell repertoire when gated on
the total, T cell population was performed.
Vβ8 was found to be significantly raised in
the non-SAg-producing AD group when
compared with normals, plaque psoriasis
patients, and AD patients with SAg-
producing S. aureus (p , 0.05).
Figure 4. Analysis of Vb8F repertoire
in the CD4F and CD8F T cell
subpopulations. (a) The expansion of
Vβ81 T cells is not observed within the
CD41 population. Immunophenotyping
of the CD41/Vβ81, T cell repertoire when
gated on the total T cell population was
performed. The closed triangles represent
two individual AD patients with non-SAg-
producing S. aureus that showed elevated
Vβ81 T cells in the CD41 population
only. (b) The expanded population of Vβ81
T cells is observed solely within the CD81
population. Immunophenotyping of the
CD81, T cell repertoire when gated on
the total T cell population was performed.
Vβ8 was found to be significantly raised in
the non-SAg-producing AD group when
compared with normals, plaque psoriasis
patients, and AD patients with SAg-
producing S. aureus (p , 0.05). The closed
triangles represent individual AD patients
with non-SAg-producing S. aureus who
had elevated Vβ81 T cells in the CD41
population.
production by non-T accessory cells (Lester, 1995). Along with its
effects in promoting IFN-γ production (Wu, 1993), IL-12 is a
potent upregulator of CLA expression on activated T cells (Leung
et al, 1995).
SAg activation, and the IL-12 upregulation of CLA, operates on
both naı¨ve and memory T cells (Leung et al, 1995), suggesting that
the expansion of Vβ-specific CLA1 T cells reported here may
originate from (i) the activation of existant CLA1 memory T cells
in the skin (SAg induced IL-12 acting to maintain and/or upregulate
the level of CLA expression on these already CLA1 T cells); (ii)
the activation of naı¨ve T cells in draining peripheral lymph node
(SAg induced IL-12 inducing CLA on these SAg activated cells, as
well as promoting a ‘‘Th 1’’ cytokine synthesis phenotype); and/
or (iii) the activation of pre-existent CLA1 and memory T cells
in draining peripheral lymph node with similar consequences.
Thus, the combined mechanism of SAg-induced proliferation and
CLA upregulation may converge to recruit a large cohort of new
skin homing, likely Th 1-type, Vβ-restricted T cells to the
recirculating, skin homing memory T cell pool. Such cells would
be capable of extravasating in any site of superficial skin inflamma-
tion where they would be available to contribute to the inflammat-
ory response if an activating ligand were present, and could
potentially account for the second phase of the AD inflammatory
skin reaction. Obviously, if the appropriate SAg is available on the
skin surface, these cells could be activated in bulk, and thereby
greatly augment the inflammatory process in such sites.
This hypothesis is supported by other clinical observations in
SAg-associated disorders. Michie and Davis (1996) reported that in
14 of 68 patients that had survived toxic shock syndrome caused
by TSST-1-producing S. aureus, a chronic eczematoid dermatitis
developed during the first 2 wk of illness. This eczematoid dermatitis
persisted for over 1 y after the acute illness, suggesting that SAg
can trigger eczema. In the same study, a control group of patients
with gram-negative septic shock did not develop eczema. TSST-1
may induce an upregulation of CLA on T cells present in the
mucosal tissue, diverting these cells to the skin and initiating the
eczema. Likewise, in Kawasaki syndrome, a disease in which SAg
have been linked to its pathogenesis, an increased prevalence of
AD has been reported in patients recovering from the illness
(Brosius et al, 1988; Leung et al, 1993b).
The concept that SAg are involved in the pathogenesis of AD
is supported by work from several other groups. Neuber et al
(1996) showed a preferential over-representation of Vβ3, 8, and
12 positive T cells in lesional AD skin. These are T cells known
to be SAg reactive. Moreover, the data also suggested a selective
stimulation of Th 2 type T cells via SAg stimulation. It is also of
interest to note that circulating IgE antibodies directed against SEA
and SEB have been reported in several reports (Jozefckz, 1974;
Leung et al, 1993a). Tada et al (1996) reported that up to 80% of
AD patients have detectable circulating IgE directed against SAg.
Thus, SAg may also act as allergens and trigger mast cell degranula-
tion in AD patients. More recently, Herz et al (1998), investigated
the role of SAg in allergic skin inflammation, by developing a
humanized severe combined immuno-deficient mouse model. In
this model, mice were reconstituted with PBMC from Dermato-
phagoides pteronyssinus-sensitive AD patients and nonatopic controls.
Epicutaneous challenge with either Dermatophagoides pteronyssinus
or SEB alone, triggered a modest T cell infiltrate of the dermis;
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however, when these mice were challenged with both stimuli
simultaneously, a significantly greater inflammatory skin infiltrate
was observed. These data suggest that a synergistic mechanism
exists between allergen and superantigenic stimulation of the
immune system.
In our study, AD subjects without SAg-producing S. aureus
lacked consistent expansions of T cells bearing SAg-reactive TCR,
but did display elevations of T cells bearing other TCR. These
elevations were present in either the CD41 or the CD81 T cell
subsets, but not both. Some were visualized only in the CLA1
memory T cell subset, whereas others, particularly the prominent
expansions of Vβ81, CD81 T cells, were discernible within the
overall T cell population. Sequence analysis of these Vβ8 expansions
demonstrated oligoclonality. Taken together, these data suggest
these expansions are antigen driven, and not related to novel SAg.
Recent data have indicated that allergen-specific CD41 T cells are
preferentially represented in the CLA1 memory subset in AD
patients (Santamaria-Babi et al, 1995), and thus it is possible that
the CD41 CLA1 subset expansions observed in this study represent
allergen stimulated clones. Overall our data illustrate the heterogen-
eity of agents able to trigger or augment the inflammatory response
in this common skin disease with involvement of both allergens
and microbial SAg.
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